Business Wire

YuppTV Teams up with Dharma Productions to Offer the Best of Movie Catalogue on YuppFlix

Del

YuppTV, world’s leading OTT brand for South-Asian content has entered into an alliance with Dharma Productions, one of the most successful productions houses in India today. As part of the association, YuppTV users across the globe, excluding India, can now watch various blockbusters by Dharma Productions, including Kapoor & Sons, Ok Jaanu, Brothers, Baahubali: The Beginning (Hindi), Humpty Dharma ki Dulhania and more. The movies will be available on YuppFlix, an on-demand movie streaming platform by YuppTV.

Commenting on the association, Mr. Uday Reddy, Founder & CEO of YuppTV said, “We are happy to announce our partnership with the Dharma Production, one of the most renowned hubs for cinematic brilliance. The association is set to present our global users with an exciting collection of blockbusters by Dharma, including Baahubali: The Beginning (Hindi), Kapoor & Sons and more. We are affirmative that our users across the Globe will enjoy the latest and popular cinema on YuppFlix.”

YuppTV has been actively refreshing its movie catalogue. YuppFlix, the on-demand movie streaming platform by YuppTV, offers its users latest and exciting collection of movies that are rigorously updated. Users can access the latest movies by Dharma Productions on YuppFlix.

About YuppTV

YuppTV is one of the world’s largest internet-based TV and On-demand service provider for South Asian content, offering more than 250+ TV channels, 5000+ Movies and 100+ TV Shows in 14 languages. YuppTV, recently received funding from Emerald Media, a Pan-Asian platform established by leading global investment firm KKR for investing in the media and entertainment sector, wherein Emerald Media acquired a significant minority stake in the company for US$50mn. Emerald Media is led by industry veterans Rajesh Kamat and Paul Aiello, supported by an experienced team of investment and operating executives. The platform primarily focuses on providing growth capital to media, entertainment and digital media companies. YuppTV had earlier raised its Series A round of funding from Poarch Creek Indian Tribe of Alabama.

YuppTV has 25000 hours of entertainment content catalogued in its library, while nearly 2500 hours of new on-demand content is added to the YuppTV platform every day. YuppTV offers Live TV and Catch-Up TV technology. It also offers YuppFlix, a movie on demand streaming service for Expat Market and recently launched YuppTV Originals to bring forth unconventional story telling in collaboration with the top talent from the movie industry. Originals will be available in episodic format for the digital audience, exclusively on YuppTV’s platform. YuppTV is currently ranked #1 Internet Pay TV platform for Indians living abroad and the largest Internet TV platform from premium content availability in India. YuppTV is the most downloaded Indian SmartTV app and it also boasts of 13 million mobile downloads with 4.0 user rating.

Visit www.yuppflix.com for more information.

Contact information

YuppTV
Pooja Diwan, +91 40 23555055

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01Pressemelding

Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a

Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21Pressemelding

Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom